BICO Group AB Class B · OMXSTO:BICO

BICO Group AB Class B — Q3 2026 Earnings Presentation

29 slides from BICO Group AB Class B's earnings presentation, Nov 11, 2026

  1. Slide 1: Interim Report Q3 2026 Earnings Call

    Slide 1: Interim Report Q3 2026 Earnings Call

    INTERIM REPORT Q3 2026 EARNINGS CALL – WEDNESDAY, NOVEMBER 11, 2026

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    DISCLAIMER You must read the following before continuing. The fol- for publication, release or distribution in the United affect the extent to which a particular projection is real- lowing applies to this document and the information pro- States, the United Kingdom, Australia, Canada or Japan, ised.

  3. Slide 3: Q3 2026 Earnings Call Agenda

    Slide 3: Q3 2026 Earnings Call Agenda

    Q3 2026 Earnings Call Agenda BICO 2030 Strategy Group Financial Performance Q3 2026 Focus Q4 2026 Q&A 3

  4. Slide 4: BICO 2030 Strategy

    Slide 4: BICO 2030 Strategy

    BICO 2030 Strategy

  5. Slide 5: From BICO 2.0 to The BICO 2030 Strategy

    Slide 5: From BICO 2.0 to The BICO 2030 Strategy

    From BICO 2.0 to The BICO 2030 Strategy A three-step process that moved from business review to commercial plans and one group strategy. SPRING 2026 SUMMER 2026 AUTUMN 2026 Business review Commercial plans BICO 2030 Strategy 01 02 03 Comprehensive review The business review With input from the Produ

  6. Slide 6: Precision Biology - In Total BICO is Serving a $10B TAM

    Slide 6: Precision Biology - In Total BICO is Serving a $10B TAM

    Precision Biology - In Total BICO is Serving a $10B TAM Three growing markets; ~$1.5B serviceable today (SAM), growing ~4-7% p.a. 3D Biology & Biomaterials $2.7B TAM – low double-digit growth Shift from animal tests to human-relevant 3D models Cell Imaging, Isolation & CLD Automation of the Wet Lab

  7. Slide 7: The Problem Worth Solving

    Slide 7: The Problem Worth Solving

    The Problem Worth Solving 18,500 Recognized diseases to treat, but only 4,000 out of these have an FDA-approved THE NEED treatment = about 1 in 5 THE TOTAL R&D SPEND THE TIME INVESTED THE COST OF FAILING LATE $300B 10-15 years $2.7B Annual pharma R&D spend Bringing a drug to the market. In Average R

  8. Slide 8: Where BICO Comes into Play

    Slide 8: Where BICO Comes into Play

    Where BICO Comes into Play 3-5 YEARS 10 YEARS Discovery Preclinical Phase I Phase II Phase III Approval Understand the disease Test in cell models, Safe in humans? Does it work in patients? Confirm at scale Regulatory review mechanism and identify organoids, 3D tissue models targets. Screen compound

  9. Slide 9: Presenting BICO 2030 Strategy

    Slide 9: Presenting BICO 2030 Strategy

    Presenting BICO 2030 Strategy Accelerate Precision Biology BICO is the precision biology company. Each brand brings a specific capability for handling living material precisely, including the growth matrix, conditions, placement and analysis. Our lead market is cell-based applications in biotech and

  10. Slide 10: BICO's Core Capabilities within Precision Biology

    Slide 10: BICO's Core Capabilities within Precision Biology

    BICO’s Core Capabilities within Precision Biology A portfolio of instruments, software and biomaterials that supports more precise, reproducible and scalable biological work. HANDLING CULTURE ANALYSIS Preparing, moving and placing biological material. Creating and maintaining the conditions biology

  11. Slide 11: Strategy and Value Creation in Brief

    Slide 11: Strategy and Value Creation in Brief

    Strategy and Value Creation in Brief CORNERSTONE STRATEGIC FOCUS TO ACHIEVE BICO 2030 VALUE CREATION • Accelerate organic growth • Increase the share of consumables, services Precision Biology Concentrate resources on cell solutions and 3D cell models, and software in the revenue mix at the core whe

  12. Slide 12: BICO's Financial Targets Remain Unchanged

    Slide 12: BICO's Financial Targets Remain Unchanged

    BICO’s Financial Targets Remain Unchanged Reinforced focus on sustainable profit growth generation and long-term value creation. FINANCIAL TARGETS Double-digit organic growth >10% EBITDA margin less capitalized development cost Net debt / EBITDA <3.0x WHAT PERFORMANCE SHOWED WHAT BIOSERO TAUGHT US W

  13. Slide 13: Executive Management aligned to BICO 2030

    Slide 13: Executive Management aligned to BICO 2030

    Executive Management aligned to BICO 2030 Anders Fogelberg Ewa Linsäter President & CEO CFO BICO is strengthening the Executive Management to improve business accountability and support customer- centric strategic execution. Julian Riba Petros Apostolopoulos Avijit Minocha CTO Managing Director Mana

  14. Slide 14: Ownership. Innovation. Impact. This is BICO.

    Slide 14: Ownership. Innovation. Impact. This is BICO.

    Ownership. Innovation. Impact. This is BICO. Ownership Innovation Impact We are empowered to take We are driven by curiosity, We are inspired by the ownership of our actions, guided by passion, and have the difference our work makes. decisions, and results. courage to explore new ideas. Through the

  15. Slide 15: Invitation to Strategy Deep Dive on November 25

    Slide 15: Invitation to Strategy Deep Dive on November 25

    Invitation to Register at: Strategy www.bico.com/ Deep Dive on investors November 25

  16. Slide 16: Group Performance Q3 2026

    Slide 16: Group Performance Q3 2026

    Group Performance Q3 2026

  17. Slide 17: Summary Q3 2026

    Slide 17: Summary Q3 2026

    Summary Q3 2026 CASH FLOW FROM NET SALES ADJUSTED EBITDA OPERATING ACTIVITIES SEK 465m SEK 124m SEK -41m ORGANIC SALES ADJUSTED NWC/LTM SALES GROWTH EBITDA MARGIN 19% 27% 15% All numbers in this presentation refer to continuing operations unless otherwise stated. MatTek and Visikol have been classif

  18. Slide 18: Sales Development LTM (SEKm)

    Slide 18: Sales Development LTM (SEKm)

    Sales Development LTM (SEKm) SEKm • Sales SEK 465m, with organic growth 1,800 of 19% 1,600 • The extended SCIENION supply and 1,400 license agreements generated revenue of SEK 135m 1,200 • Strong benchtop instrument and 1,000 consumables sales 800 • Improved gross profit due to the 600 SCIENION agre

  19. Slide 19: Adjusted EBITDA (SEKm) and Margin (%)

    Slide 19: Adjusted EBITDA (SEKm) and Margin (%)

    Adjusted EBITDA (SEKm) and Margin (%) SEKm % 140 30 124 • Adjusted EBITDA SEK 124m 120 27% 25 • EBITDA includes a significant 100 20 contribution from the SCIENION agreements 80 15 56 • Operating expenses continued to 60 13% decline, reflecting our continued 10 focus on cost discipline and 20 40 eff

  20. Slide 20: Goodwill and Technology Impairment related to Biosero

    Slide 20: Goodwill and Technology Impairment related to Biosero

    Goodwill and Technology Impairment related to Biosero • BICO has reviewed its position in the large-scale integrated lab automation project business • Scale, capital, and proprietary robotics hardware- requirements for market leadership • Lab Automation remains an important market for our Precision

  21. Slide 21: Cash Flow and Financial Position

    Slide 21: Cash Flow and Financial Position

    Cash Flow and Financial Position • Cash flow from operating activities, SEK –41m • includes impact from changes in working capital of SEK –178m, mainly related to; • the license revenue recognized in the quarter converts to cash over the contract term • Decline in long-term lab automation projects •

  22. Slide 22: Development in Net Working Capital between Q3 2025 and Q3 2026

    Slide 22: Development in Net Working Capital between Q3 2025 and Q3 2026

    Development in Net Working Capital between Q3 2025 and Q3 2026 SEKm % 800 30.0% 600 20.0% 400 15.4% 12.5% 12.6% WC Liabilities 10.4% 244 10.0% 200 195 Other Receivables 188 7.3% 156 Accounts Receivables 109 Inventories 0 0.0% Total NWC NWC / LTM Sales -200 -10.0% -400 -600 -20.0% Q3 25 Q4 25 Q1 26 Q

  23. Slide 23: Focus Q4 2026

    Slide 23: Focus Q4 2026

    Focus Q4 2026

  24. Slide 24: Focus Q4 2026

    Slide 24: Focus Q4 2026

    Focus Q4 2026 Host BICO 2030 strategy Deep dive on November 25 Anchor strategy internally and focus on top priorities for each Business Unit Assess options for Biosero to determine its ideal long-term potential Strengthen the Group’s capabilities within AI Ramp up for key launches 2027

  25. Slide 25: Invitation to Strategy Deep Dive on November 25

    Slide 25: Invitation to Strategy Deep Dive on November 25

    Invitation to Register at: Strategy www.bico.com/ Deep Dive on investors November 25 25

  26. Slide 26: Ownership. Innovation. Impact. This is BICO.

    Slide 26: Ownership. Innovation. Impact. This is BICO.

    Ownership. Innovation. Impact. This is BICO. Ownership Innovation Impact We are empowered to take We are driven by curiosity, We are inspired by the ownership of our actions, guided by passion, and have the difference our work makes. decisions, and results. courage to explore new ideas. Through the

  27. Slide 27: Q&A

    Slide 27: Q&A

    Q&A

  28. Slide 28: Financial Calendar

    Slide 28: Financial Calendar

    ANDERS FOGELBERG, PRESIDENT AND CEO EWA LINSÄTER, CFO BICO GROUP AB BICO GROUP AB Phone: EA Elisabeth Lindell, +46 761 73 40 59 Phone: +46 766 33 32 33 E-mail: elisabeth.lindell@bico.com E-mail: ewa.linsater@bico.com BICO strives towards the vision to enable life-science labs to accelerate the disco

  29. Slide 29

    Slide 29

Source: 6ix earnings call

More decks from BICO Group AB Class B

All 22 BICO Group AB Class B decks